Compare Ascendis Pharma A/S (ASND) vs DoorDash Inc (DASH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs DoorDash Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while DoorDash Inc trades at $192 (market cap $83.58B). The key difference: DoorDash Inc is far larger — about 4.7× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| ASND | DASH | |
|---|---|---|
Market Cap | $17.74B | $83.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $281.74 |
52-Week Low | $163.32 | $146.60 |
Enterprise Value | $18.11B | $81.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DoorDash (DASH) trades at $191.82, down 0.28% on the day, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, reaching $13.72 billion in 2025, and has turned profitable with a net income margin of 6.29%. Recent news highlights expansion into grocery delivery and AI integration, while technical indicators suggest key resistance near $200.
The outlook remains positive due to market dominance and international expansion, but risks include intense competition and valuation concerns with a P/E of 90.91. Analysts project a consensus price target of $231.50, implying significant upside, though upcoming Q2 2026 earnings on August 5 will be critical for momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
